Grifols SA

1GRF

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,822

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,571.4040.30-0.47%
CAC 407,864.4446.05-0.58%
DAX 4023,999.17123.23-0.51%
Dow JONES (US)41,859.031.41-0.00%
FTSE 1008,739.2647.20-0.54%
HKSE23,544.31283.47-1.19%
NASDAQ18,953.3980.740.43%
Nikkei 22536,985.87313.11-0.84%
NZX 50 Index12,662.2540.85-0.32%
S&P 5005,843.750.86-0.01%
S&P/ASX 2008,348.7038.10-0.45%
SSE Composite Index3,380.197.39-0.22%

Market Movers